Reuters logo
BRIEF-FDA grants priority review to Merck's supplemental marketing application for Keytruda
May 23, 2017 / 11:17 AM / 4 months ago

BRIEF-FDA grants priority review to Merck's supplemental marketing application for Keytruda

May 23 (Reuters) - Merck & Co Inc-

* FDA grants priority review to Merck’S supplemental biologics license application (sbla) for Keytruda® (pembrolizumab) for treatment of recurrent or advanced gastric or gastroesophageal junction adenocarcinoma

* Merck & Co Inc - fda granted priority review with a pdufa, or target action, date of sept. 22, 2017

* Merck & Co -application submitted seeks approval for keytruda monotherapy in previously treated patients at 200 mg dose administered intravenously every 3 weeks Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below